Search

Your search keyword '"Mao, Junqin"' showing total 11 results
Start Over Author "Mao, Junqin"
11 results on '"Mao, Junqin"'

3. Determining the effective dose of esketamine combined with propofol for painless hysteroscopy: a prospective dose-finding study.

Author

Sheng, Zhimin, Liu, Xiang, Lin, Kang, Liu, Jie, Mao, Junqin, and Qian, Xiaowei

Subjects
INTRAVENOUS anesthesia, HYSTEROSCOPY, PROPOFOL, OPERATIVE surgery, CONFIDENCE intervals
Abstract

Background: The combination of esketamine and propofol has become a common choice for total intravenous anesthesia in hysteroscopic procedures. However, the optimal effective dose has not yet been determined. The aim of this study was to determine the median effective dose (ED50) and 95% effective dose (ED95) of esketamine compounded with propofol for painless hysteroscopy. Methods: A total of 40 patients aged 20–60 years and scheduled for painless hysteroscopy under intravenous anesthesia were recruited, and a total of 31 patients were enrolled for the final analysis. Using the Dixon's up and down method, an initial dose of 0.5 mg/kg esketamine was administered intravenously before surgery, and after 1 min, it was followed by 2 mg/kg of propofol. If the hysteroscopy failed (a positive reaction) [defined as inadequate cervical dilatation, patient body movements interfering with surgical procedures during hysteroscopy placement, frowning, or Ramsay Sedation Scale (RSS) score <5 within 5 min], the subsequent patient's esketamine dosage was increased by 0.1 mg/kg. Conversely (a negative reaction), the dosage was decreased by 0.1 mg/kg. The test was not stopped until at least 7 crossovers occurred. The perioperative adverse events of each patient were recorded. The ED50 and ED95 with 95% confidence intervals (CIs) were estimated using probit regression. Results: The ED50 and ED95 with 95% (CIs) of esketamine in patients were 0.287 (0.220–0.342) mg/kg and 0.429 (0.365–0.705) mg/kg, respectively. No serious adverse events were observed in any patients. Conclusion: A dose of 0.429 mg/kg esketamine combined with propofol is recommended for painless hysteroscopy anesthesia, as it enhances anesthesia and postoperative analgesia efficacy without significant adverse reactions. However, potential risks associated with this dosage should be carefully considered in clinical practice. Clinical Trial Registration: https://www.chictr.org.cn/index.html, identifier ChiCTR2300075564. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Synthesis of Novel Xanthone Analogues and Their Growth Inhibitory Activity Against Human Lung Cancer A549 Cells

Author

Wu, Junqi, Dai, Jinwei, Zhang, Yuyang, Wang, Jing, Huang, Lei, Ding, Hongmei, Li, Tiejun, Zhang, Yuefan, Mao, Junqin, and Yu, Shichong

Subjects
Drug Design, Development and Therapy, synthesis, Dose-Response Relationship, Drug, Molecular Structure, Xanthones, apoptosis, Antineoplastic Agents, Structure-Activity Relationship, A549 Cells, xanthone, derivatives, Humans, Drug Screening Assays, Antitumor, lung cancer cell, Original Research, Cell Proliferation
Abstract

Junqi Wu,1,2,* Jinwei Dai,1,3,* Yuyang Zhang,1,3 Jing Wang,1 Lei Huang,1 Hongmei Ding,1 Tiejun Li,1,4 Yuefan Zhang,1,5 Junqin Mao,6 Shichong Yu1 1College of Pharmacy, Naval Medical University, Shanghai 200433, People’s Republic of China; 2Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, People’s Republic of China; 3Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, People’s Republic of China; 4Department of Pharmacy, Punan Hospital, Shanghai 200125, People’s Republic of China; 5Biomedical Innovation R&D Center, School of Medicine, Shanghai University, Shanghai, 20444, People’s Republic of China; 6Department of Pharmacy, Shanghai Pudong New Area People’s Hospital, Shanghai 201299, People’s Republic of China*These authors contributed equally to this workCorrespondence: Junqin Mao Email maojq204@163.comShichong Yu Tel/Fax +86-21-81871228Email yuscc1008@163.comPurpose: Xanthones demonstrated an array of pharmacological activities via non-covalent DNA interaction and have been widely utilized in new drug research. The introduction of the polar 1,2,3-triazole ring located at the C3-position of xanthone has not been reported thus far.Methods: In the present study, a series of xanthone derivatives were designed, synthesized, and characterized through 1H NMR, 13C NMR, and MS. The methyl thiazolyl tetrazolium method was used to evaluate the cytotoxic activity of compounds. Furthermore, the structure–activity relationship and the potential mechanism of target compounds were investigated.Results: The IC50 showed that the inhibitory activity of 18 target compounds was higher than that of the original xanthone intermediate 4. In particular, compound 1j was the most active agent against A549 cancer cells (IC50 = 32.4 ± 2.2 μM). Moreover, apoptosis analysis indicated different contributions of early/late apoptosis to cell death for compounds 1h and 1j. The results of Western blotting analysis showed that compound 1j significantly increased the expression of caspase 3, Bax, and c-Jun N-terminal kinase, and regulated p53 to a better healthy state in cancer cells.Conclusion: We synthesized several derivatives of xanthone and evaluated their cytotoxicity. The evidence suggested that compound 1j possessed greater anticancer potential for further evaluations.Keywords: synthesis, xanthone, derivatives, lung cancer cell, apoptosis

Published
2019

10. Synthesis of Novel Xanthone Analogues and Their Growth Inhibitory Activity Against Human Lung Cancer A549 Cells

Author

Wu,Junqi, Dai,Jinwei, Zhang,Yuyang, Wang,Jing, Huang,Lei, Ding,Hongmei, Li,Tiejun, Zhang,Yuefan, Mao,Junqin, Yu,Shichong, Wu,Junqi, Dai,Jinwei, Zhang,Yuyang, Wang,Jing, Huang,Lei, Ding,Hongmei, Li,Tiejun, Zhang,Yuefan, Mao,Junqin, and Yu,Shichong

Abstract

Junqi Wu,1,2,* Jinwei Dai,1,3,* Yuyang Zhang,1,3 Jing Wang,1 Lei Huang,1 Hongmei Ding,1 Tiejun Li,1,4 Yuefan Zhang,1,5 Junqin Mao,6 Shichong Yu1 1College of Pharmacy, Naval Medical University, Shanghai 200433, People’s Republic of China; 2Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, People’s Republic of China; 3Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, People’s Republic of China; 4Department of Pharmacy, Punan Hospital, Shanghai 200125, People’s Republic of China; 5Biomedical Innovation R&D Center, School of Medicine, Shanghai University, Shanghai, 20444, People’s Republic of China; 6Department of Pharmacy, Shanghai Pudong New Area People’s Hospital, Shanghai 201299, People’s Republic of China*These authors contributed equally to this workCorrespondence: Junqin Mao Email maojq204@163.comShichong Yu Tel/Fax +86-21-81871228Email yuscc1008@163.comPurpose: Xanthones demonstrated an array of pharmacological activities via non-covalent DNA interaction and have been widely utilized in new drug research. The introduction of the polar 1,2,3-triazole ring located at the C3-position of xanthone has not been reported thus far.Methods: In the present study, a series of xanthone derivatives were designed, synthesized, and characterized through 1H NMR, 13C NMR, and MS. The methyl thiazolyl tetrazolium method was used to evaluate the cytotoxic activity of compounds. Furthermore, the structure–activity relationship and the potential mechanism of target compounds were investigated.Results: The IC50 showed that the inhibitory activity of 18 target compounds was higher than that of the original xanthone intermediate 4. In particular, compound 1j was the most active agent against A549 cancer cells (IC50 = 32.4 ± 2.2 μM). Moreover

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results